# A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)

> **NCT03913143** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **ProQR Therapeutics** · enrollment: 36 (actual)

## Conditions studied

- Leber Congenital Amaurosis 10
- Blindness
- Leber Congenital Amaurosis
- Vision Disorders
- Sensation Disorders
- Neurologic Manifestations
- Eye Diseases
- Eye Diseases, Hereditary
- Eye Disorders Congenital
- Retinal Disease

## Interventions

- **DRUG:** sepofarsen
- **OTHER:** Sham

## Key facts

- **NCT ID:** NCT03913143
- **Lead sponsor:** ProQR Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-04-04
- **Primary completion:** 2022-01-31
- **Final completion:** 2023-03
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2022-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03913143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03913143, "A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT03913143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*